NOTE:
This C. ECMO for patients with any of the following relative contraindications may be considered on a case by case basis:
1. When anticoagulation is contraindicated (e.g., bleeding, recent surgery, recent intracranial injury).
2. For patients with respiratory failure, if mechanically ventilated for longer than seven days.
3. For patients with cardiac failure, when a VAD or transplantation is contraindicated (e.g., the patient has preexisting renal failure, preexisting hepatic failure, significant aortic valve insufficiency, or inadequate social support).
4. Other characteristics that may exclude some patients from receiving ECMO include advanced age, morbid obesity, neurologic dysfunction, or poor preexisting functional status.
D. Standard durations with ECMO vary by condition. It is initiated with the expectation that cardiorespiratory function will improve sufficiently to allow discontinuation of ECMO within 14-21 days.
E. ECMO should be discontinued if there is no hope for healthy survival (severe brain damage, no heart or lung recovery, or no hope of organ replacement by VAD or transplant).
F. Patients undergoing ECMO treatment should be periodically reassessed for clinical improvement. ECMO should not be continued indefinitely and should be considered for discontinuation if the following criteria are met:
1. The patient has neurologic devastation as defined by the following: 3. Presumed end-stage cardiac or lung failure without "exit" plan (i.e., declined for assist device and/or transplantation).
III. Limitations/Exclusions
A. Prior authorization is not required because ECMO is generally provided on an emergency basis. However, after the initiation of ECMO, a written and signed treatment plan must be made available to UHA upon request, which documents the following:
1. Discussion with patient or patient's representative of advance care planning;
2. Explanation of ECMO's use as a temporary measure for life-threatening conditions; and 3. Estimated timetable for withdrawal of ECMO support, given scenarios of various clinical parameters (e.g., discontinuation of ECMO if no clinical improvement in identified time frame).
Note: Use beyond 21 days must be justified on clinical grounds specific to the affected patient.
B. UHA reserves the right to perform retrospective review using the above or other generally accepted criteria to validate if services rendered met payment determination criteria and to ensure proper reimbursement is made.
C. ECMO services provided for more than 14 days or that have a contraindication listed in Limitations/ Exclusions above will be reviewed by a Medical Director. Supporting documentation must be submitted with the claim for review.
D. This policy may apply to the following codes. Inclusion of a code in the table below does not guarantee that it will be reimbursed. 
CPT Code Description

IV. Administrative Guidelines
